[HTML][HTML] Overcoming cancer therapeutic bottleneck by drug repurposing
Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …
the development of the alternative strategy of drug repurposing, the development of old …
An overview of drug discovery and development
N Berdigaliyev, M Aljofan - Future medicinal chemistry, 2020 - Taylor & Francis
A new medicine will take an average of 10–15 years and more than US $2 billion before it
can reach the pharmacy shelf. Traditionally, drug discovery relied on natural products as the …
can reach the pharmacy shelf. Traditionally, drug discovery relied on natural products as the …
Drug repurposing in cancer
L Sleire, HE Førde, IA Netland, L Leiss, BS Skeie… - Pharmacological …, 2017 - Elsevier
Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …
increase in the coming years. Whereas the limited success with current therapies has driven …
Drug combination therapy increases successful drug repositioning
Highlights•Publications for drug repositioning have drastically increased in past five
years.•Different types of drug repositioning and available resources have been …
years.•Different types of drug repositioning and available resources have been …
Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP
Y Liu-Chittenden, B Huang, JS Shim… - Genes & …, 2012 - genesdev.cshlp.org
The Drosophila TEAD ortholog Scalloped is required for Yki-mediated overgrowth but is
largely dispensable for normal tissue growth, suggesting that its mammalian counterpart …
largely dispensable for normal tissue growth, suggesting that its mammalian counterpart …
[HTML][HTML] Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
P Pantziarka, G Bouche, L Meheus… - …, 2014 - ncbi.nlm.nih.gov
Cimetidine, the first H 2 receptor antagonist in widespread clinical use, has anti-cancer
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …
[HTML][HTML] Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive
efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act …
efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act …
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-
inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by> …
inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by> …
[HTML][HTML] An update on Drug Repurposing: Re-written saga of the drug's fate
Drug repurposing is an unconventional drug discovery approach to explore new therapeutic
benefits of existing, shelved and the drugs in clinical trials. This approach is currently …
benefits of existing, shelved and the drugs in clinical trials. This approach is currently …
[HTML][HTML] Recent advances in drug repositioning for the discovery of new anticancer drugs
Drug repositioning (also referred to as drug repurposing), the process of finding new uses of
existing drugs, has been gaining popularity in recent years. The availability of several …
existing drugs, has been gaining popularity in recent years. The availability of several …